MVP-104 Tri-Specific

MVP-104 Tri-Specific is a preclinical-stage trispecific antibody and T-cell engager being developed by Multiverse Pharma for the treatment of oncology indications. As a trispecific molecule, it is designed to simultaneously bind to three distinct targets, typically including a T-cell surface antigen (such as CD3) and two tumor-associated antigens to enhance specificity and potency in redirecting T-cell-mediated cytotoxicity against malignant cells. While the specific molecular targets for MVP-104 have not been publicly disclosed by the sponsor, the program leverages Multiverse Pharma's platform for multi-specific biologics to address unmet needs in cancer therapy.